contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


annexin-participates-in-several-investor-and-industry-events

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Annexin Pharmaceuticals is a biotechnology company developing the drug candidate ANXV, based on the protein Annexin A5, for the treatment of diseases such as vascular damage, inflammation and certain cancers. The company's partners are healthcare providers and biopharmaceutical companies and the business is aimed at global markets through research and licensing collaborations. The company was founded in 2014 and is headquartered in Stockholm, Sweden.

Annexin Pharmaceuticals

Annexin Pharmaceuticals AB (publ) today announces that the company will participate in several leading international investor and industry events this summer. The aim is to increase awareness...

<div class="mfn-preamble">Annexin Pharmaceuticals AB (publ) today announces that the company will participate in several leading international investor and industry events this summer. The aim is to increase awareness of the company and the drug candidate ANXV, as well as to deepen dialogues with potential partners and investors.</div><div class="mfn-body"><ul><li>BIO International Convention 2025, June 16-19, Boston, USA One of the world's largest biotech congresses with participants from the entire pharmaceutical industry. Read more here: <a rel="noopener" href="https://convention.bio.org/bio-2025">BIO 2025</a> </li><li>Clinical Trials at the Summit (CTS) 2025, June 19-22, Las Vegas, USA A leading forum for clinical trials in eye diseases, with a focus on innovation and collaboration. Annexin has been selected and invited to present. Read more here: <a rel="noopener" href="https://www.ctsretina.org/">Clinical Trials at the Summit 2025</a> </li><li>Ophthalmology Innovation Source, OIS Retina Innovation Summit 2025, July 29, Long Beach, California, USA An exclusive event for innovation in ophthalmology, bringing together leading players in the retina field. Annexin has been selected and invited to present. Read more here: <a rel="noopener" href="https://ois.net/retina-innovation-summit/">OIS Retina Innovation 2025</a> </li><li>American Society of Retina Specialists, ASRS 2025, July 30 – August 1, Long Beach, California, USA Immediately after the above event, eye care specialists will continue to gather to spark new conversations and create opportunities for future collaboration. Read more here: <a rel="noopener" href="https://www.asrs.org/annual-meeting">ASRS 2025</a> </li><li>EURETINA 2025, 4-7 September, Paris, France Europe's largest scientific congress in retina, focusing on clinical research and new treatments. Annexin has been selected and invited to present. Read more here: <a rel="noopener" href="https://meetingservices.org/euretina-2025/">Euretina 2025</a></li></ul>"We look forward to presenting our progress and discussing ANXV's potential with both industry peers and investors at these important meetings. It is part of our strategy to increase the international visibility of our project in retinal vein occlusion (RVO) and other eye diseases," says Anders Haegerstrand, CEO of Annexin Pharmaceuticals.For further information, please contact: Anders Haegerstrand, CEO Phone: +46 70 575 50 37 E-mail: <a rel="noopener" href="mailto:anders.haegerstrand@annexinpharma.com">anders.haegerstrand@annexinpharma.com</a>Anna Frostegård, CSO/CMO Phone: +46 70 110 42 58 E-mail: <a rel="noopener" href="mailto:anna.frostegard@annexinpharma.com">anna.frostegard@annexinpharma.com</a></div><div class="mfn-footer mfn-about mfn-d80162962aba">About Annexin Pharmaceuticals AB Annexin Pharmaceuticals AB is a leading biotechnology company in the Annexin A5 field for the treatment of various diseases. The company’s biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is primarily intended for treatment of patients with injuries and inflammation of the blood vessels, but also for cancer. The company has an extensive patent portfolio for the treatment of diseases with Annexin A5 and for production of Annexin A5. The Company is based in Stockholm, Sweden and listed on Nasdaq First North Growth Market, under the ticker ANNX. Redeye is the company´s Certified Adviser.</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments <a rel="noopener" href="https://storage.mfn.se/2dd19147-5f4a-4b89-8353-8fba01806d25/annexin-participates-in-several-investor-and-industry-events.pdf" class="mfn-generated mfn-primary">Annexin participates in several investor and industry events</a></div>